BFO
DGX icon

Biltmore Family Office’s Quest Diagnostics DGX Stock Holding History

Biltmore Family Office’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$265K Buy
1,250
+11
+0.9% +$2.16K 0.03% 226
2026
Q1 		$243K Hold
1,239
– – 0.03% 222
2025
Q4 		$215K Hold
1,239
– – 0.03% 223
2025
Q3 		$236K Hold
1,239
– – 0.03% 201
2025
Q2 		$223K Hold
1,239
– – 0.04% 195
2025
Q1 		$210K Buy
+1,239
New +$204K 0.04% 200
2022
Q1 		– Sell
-2,478
Closed -$429K – 222
2021
Q4 		$429K Hold
2,478
– – 0.08% 139
2021
Q3 		$360K Buy
+2,478
New +$363K 0.09% 133

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Biltmore Family Office's DGX Position: Q2 2026 in Review

Biltmore Family Office increased its Quest Diagnostics (DGX) stake by 0.89% in Q2 2026, buying an estimated $2.16K and bringing the position to 1,250 shares worth $265K. The position accounts for 0.03% of the portfolio, ranked #226.

Biltmore Family Office first reported a position in DGX in Q3 2021 and has held it in 8 quarters since. The position peaked at $429K in Q4 2021. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Biltmore Family Office held 1,250 shares of Quest Diagnostics worth $265K as of Q2 2026.
  • Biltmore Family Office bought 11 Quest Diagnostics shares in Q2 2026, an estimated $2.16K.
  • Quest Diagnostics made up 0.03% of Biltmore Family Office's portfolio in Q2 2026, its #226 holding.
  • Biltmore Family Office first reported a position in Quest Diagnostics in Q3 2021 and has held it in 8 quarters since.
  • Biltmore Family Office's Quest Diagnostics position peaked at $429K in Q4 2021.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Biltmore Family Office's 13F filing for Q2 2026, filed 12 Aug 2026.